RxDoctor Payments Data

Anju Budhwani, MD

Internal Medicine · Lincoln Park, NJNPI 1679795835

Payments from drug & device makers

$6,554in general payments, 2019–2025

Across 403 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • Jazz Pharmaceuticals Inc.$598
  • Philips North America LLC$537
  • Grifols USA, LLC$269
  • Harmony Biosciences LLC$226
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$6,33197%
  • Education$2233%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,554 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$212,944
Medicare patients
251
Services billed
2,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$69,733
Breztri AerosphereBudesonide/Glycopyr/Formoterol51$35,364
EliquisApixaban37$30,518
Breo ElliptaFluticasone/Vilanterol21$18,327
XareltoRivaroxaban12$15,250
OzempicSemaglutide11$14,186
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$10,921
Spiriva RespimatTiotropium Bromide12$10,676
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$6,713
Rosuvastatin Calcium157$3,083
Fluoxetine Hcl17$1,873
Albuterol Sulfate HfaAlbuterol Sulfate87$1,817
Esomeprazole Magnesium27$1,610
Atorvastatin Calcium123$1,274
Omeprazole72$1,242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,031$98,982104 claims
AstraZenecaBreztri Aerosphere$2,391$35,36451 claims
Novo NordiskOzempic$147$14,18611 claims
Boehringer IngelheimSpiriva Respimat$213$10,67612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Lincoln Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →